Review outlines GBS as a neurological disorder linked to COVID-19 vaccination, emphasizing safety concerns after vaccination.
Guillain-Barré syndrome (GBS) is a rare autoimmune neurological disorder affecting the peripheral nervous system. It is commonly triggered by infections and has also been reported rarely after vaccination. During the COVID-19 pandemic, cases of GBS following COVID-19 vaccination were reported, raising safety concerns. This review summarizes recent literature (2016–2025) on the pathophysiology, clinical features, diagnosis, and management of GBS, with special importance on post-COVID-19 vaccination cases. Evidence suggests a temporal association, particularly with adenovirus-based vaccines; however, the overall incidence remains very low. Early diagnosis and rapid treatment result in favourable outcomes. The benefits of COVID-19 vaccination overshadow the rare risk of neurological complications. Keywords Guillain-Barré syndrome, COVID-19 vaccine, neurological disorder, autoimmune disease.
No takes yet. Share an insight, caveat, or question.
Aditya Singh1, Saief Ansari1, Neha Sharma2, Arushi Purva2, Harshit Gautam2, and Sandeep Singh2 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: